

Evaluation of CPT-11 in combination with doxorubicin against pancreatic ductal adenocarcinoma P03 on B6D2F1 female mice
BCM-887 (10.30.96-02.27.97)

Agent (batch)	Route	Dosage in mg/kg/dose	Schedule in days	Total dose in mg/kg	Fraction of HDT	Drug death (days of death)	Average body weight change in % per mouse at nadir (day of nadir)	Median tumor weight in mg on day 16 (range)	T/C in % day 16	Time for median tumor to reach 1000 mg in days	T-C log cell kill in days	Tumor free survivors day/20	Comments
CPT-11	p.o.	100.8	6-9	806.4	1	0/5	-16.0 (13)	75 (0-126)	8	26.2	9.8	1/3	0/5 < HDT active
	0.2 ml	62.5 (2x/day)		500.0	0/5		-3.9 (13)	126 (32-340)	14	25.7	9.3	1/2	0/5 Active
Doxorubicin	i.v.	10.0	6.9	20.0	1	0/5	-3.5 (13)	202 (0-1162)	22	20.4	4.0	0/5	0/5 Inactive
	0.2 ml	6.2	12.4	0/5		-14.1 (15)	0 (0-0)	0					
Doxorubicin	i.v/0.2ml	3.8	7.6	0/5		-4.4 (13)	126 (0-214)	14	25.9	9.5	1/2	0/5 < HDT highly active	
CPT-11	p.o/0.2ml	5.0	6.9	10.0	0.5	0/5	-5.1 (15)	382 (32-546)	42	23.9	7.5	1/0	0/5 Active
	4.1 (2x/day)	6.9	644.8	0.8) 1.3		-10.3 (13)	0 (0-0)	0					4/5 < HDT highly active
	65.5	524.0	0.65)	1.06	0/5	-6.9 (13)	0 (0-0)	0	52.0	35.6	4.7	1/5	Highly active
	3.1	6.2	0.31)	0/5		-2.5 (8)	0 (0-0)	0					
	50.4	403.2	0.50)	0.81									
	2.2	4.4	0.22)	0/5		-3.9 (13)	72 (0-126)	8	28.7	12.3	1.6	0/5	Active
	35.3	282.4	0.35)	0.57									
	1.2	2.4	0.12)	0/5		-1.8 (14)	336 (270-942)	37	20.5	4.1	0.5	0/5	Inactive
Control		20.1	160.8	0.20)	0.32			918 (343-1444)		16.4		0/10	

Tumor doubling time = 2.3 days. Mice average weight: CPT-11 = 24.39 g, doxorubicin = 25.26 g, combination = 23.50 g.
 The 2 administrations of CPT-11 were performed 4 hours apart.
 Abbreviation used: HDT = highest dose tested.

Figure 1